Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for patients with phenylketonuria (PKU) from Health Canada. Priority review provides for a shortened submission review of 180 days versus the standard twelve months. BioMarin plans to file a marketing application for Kuvan in Canada in the third quarter of 2009, and with priority review status, a decision for marketing approval is expected in the first half of 2010.

"Priority review status from Health Canada marks another milestone in our efforts to commercialize Kuvan worldwide as it is granted for serious, life-threatening or severely debilitating diseases for which no approved medical therapy exists in Canada," said Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin. "Along with our partners Merck Serono and Asubio, we remain dedicated to serving the PKU community and providing a therapeutic option in the management of this disease."

About Kuvan

Kuvan(R) (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan ha
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
(Date:4/24/2015)... 24 , 2015 PAREXEL International Corporation ... provider, today announced that Partnerships in Clinical Trials named ... the 2015 Clinical Innovator of the Year.  The honor ... for the Company,s Perceptive MyTrials ® Data-Driven Monitoring ... night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Athena ... personal development of executive women in San Diego’s technology ... the 17th Annual Pinnacle Awards at their Gala on ... Hyatt Hotel. Register now at http://athenasd.org/events/ , ... support the Athena San Diego vision of fostering networking, ...
(Date:4/23/2015)... , April 23, 2015 BioTE Medical President ... book "Age Healthier Live Happier - Avoiding Over-Medication through ... Age Management Medicine Group Conference at JW Marriott / ... ",Age Healthier Live Happier, is a welcomed ... over-medication and searching for a higher quality of life ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3
... S Introduces Innovations to Accelerate Workflow, ... (http://www.usa.siemens.com/medical ) introduces the MAMMOMAT(R) Novation S, ... clinical workflow for,screenings, at the 93rd Scientific ... of North America (RSNA) from Nov. 25 ...
... Ltd, a specialist,biopharmaceutical company developing novel peptide ... US$10M of equity finance. The syndicated,funding round ... BioCapital Funds (QBF), for $2.7M, significant equity ... top tier USA biotechnology company,headquartered in San ...
... Nov. 26 Cambridge Research &,Instrumentation, Inc. (CRi) ... in North America. The Maestro 2 received widespread ... Imaging/Academy of Molecular,Imaging joint conference for in vivo ... Workshop as well. Maestro 2, the fully,automated version ...
Cached Biology Technology:Siemens Unveils New Digital Mammography System for Optimized Screening 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 3CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems 2
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... LA JOLLA, CA August 24, 2011 A ... successfully reengineered an important antibiotic to kill the deadliest ... clinically to treat patients with life-threatening and highly resistant ... advanced online issue of the Journal of the ...
... pressure to achieve top grades are just a few of ... and seek therapy. In order to enhance the experience ... Institute of Technology and St. John Fisher College is designing ... improve their everyday skills in self-control. "The use of ...
... George Mason University researcher team has revealed the specific process ... previously unknown. The principal investigator, HIV researcher Yuntao Wu, says ... inquiry into how researchers can use this knowledge to create ... a professor of molecular and microbiology at Mason, published these ...
Cached Biology News:Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 2Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 3Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 4Game-changing project combines anxiety therapy and video games 2George Mason research team uncovers new factor in HIV infection 2
Mouse Limitin MAb (Clone 183727)...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: